News
CKPT
2.040
-1.45%
-0.030
Weekly Report: what happened at CKPT last week (0318-0322)?
Weekly Report · 3d ago
CKPT Stock Earnings: Checkpoint Therapeutics Misses EPS, Misses Revenue for Q4 2023
Checkpoint Therapeutics reported results for the fourth quarter of 2023. The company reported earnings per share of -$1.10 and revenue of $6,000. This was 70% worse than the analyst estimate for the same period of time. Checkpoint TherAPEutics is a biopharmaceutical company.
Investorplace · 5d ago
Checkpoint Therapeutics Price Target Maintained With a $34.00/Share by HC Wainwright & Co.
Dow Jones · 5d ago
HC Wainwright & Co. Reiterates Buy on Checkpoint Therapeutics, Maintains $34 Price Target
Benzinga · 5d ago
Analysts’ Top Healthcare Picks: Milestone Pharmaceuticals (MIST), Checkpoint Therapeutics (CKPT)
Milestone Pharmaceuticals and Checkpoint Therapeutics have 2 analysts bullish on the Healthcare sector. Milestone has a Buy rating from H.C. Wainwright and a $34.00 price target. Checkpoint has a Moderate Buy consensus rating from The Street.
TipRanks · 5d ago
Checkpoint Therapeutics GAAP EPS of -$3.17 misses by $0.49, revenue of $0.1M misses by $0.02M
Seeking Alpha · 5d ago
Checkpoint Therapeutics FY23 EPS $(3.17) Vs $(7.09) YoY; As Of December 31, 2023, Checkpoint's Cash And Cash Equivalents Totaled $4.9M
As of December 31, 2023, Checkpoint's cash and cash equivalents totaled $4.9 million. The company's cash position is not reflective of the registered direct offering that closed in January 2024. Research and development expenses for the year ended 2023 were $43.6 million, compared to $49.8 million in 2022.
Benzinga · 5d ago
*Checkpoint Therapeutics: Targeting FDA Resubmission for Cosibelimab by Mid-Year >CKPT
Dow Jones · 5d ago
*Checkpoint Therapeutics 2023 Loss $51.8M >CKPT
Dow Jones · 5d ago
*Checkpoint Therapeutics 2023 Loss/Shr $3.17 >CKPT
Dow Jones · 5d ago
Press Release: Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Checkpoint Therapeutics reports full-year 2023 financial results and recent corporate highlights. Checkpoint submitted a BLA to the FDA seeking approval of cosibelimab in January 2023. The FDA issued a complete response letter to Checkpoint in December 2023 for deficiencies in the company's manufacturing process. The company is working to address the deficiencies and is targeting marketing approval before the end of 2024. The Company is a clinical-stage immunotherapy company.
Dow Jones · 5d ago
Press Release: Checkpoint Therapeutics Reports -2-
Delay achievement of those milestones. The information contained in this press release is not intended to be viewed in its totality. This press release and prior releases are available at www.checkpointtherapeutics.com. Checkpoint Therapeutics, Inc. Has no obligation to update any forward-looking statements. The company's financial results for the quarter ended December 31, 2013 are reported on its website.
Dow Jones · 5d ago
Checkpoint Therapeutics Enhances Board with New Independent Director
TipRanks · 03/18 20:25
*Checkpoint Therapeutics Names Amit Sharma to Its Bd as an Independent, Non-Executive Director >CKPT
Dow Jones · 03/18 12:01
Press Release: Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. To Board of Directors. Dr. Sharma currently serves as Vice President of Clinical Development at Alexion, AstraZeneca Rare Disease. Checkpoint is a clinical-stage immunotherapy and targeted oncology company.
Dow Jones · 03/18 12:00
Weekly Report: what happened at CKPT last week (0311-0315)?
Weekly Report · 03/18 09:57
Weekly Report: what happened at CKPT last week (0304-0308)?
Weekly Report · 03/11 09:56
Weekly Report: what happened at CKPT last week (0226-0301)?
Weekly Report · 03/04 09:57
Weekly Report: what happened at CKPT last week (0219-0223)?
Weekly Report · 02/26 10:02
Weekly Report: what happened at CKPT last week (0212-0216)?
Weekly Report · 02/19 10:03
More
Webull provides a variety of real-time CKPT stock news. You can receive the latest news about Checkpoint Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CKPT
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company that is focused on the acquisition, development and commercialization of treatments for patients with solid tumor cancers. The Company is evaluating its lead antibody product candidate, cosibelimab, which is an anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute (Dana-Farber) in an ongoing global, open-label, multicohort Phase I clinical trial in checkpoint therapy-naive patients with selected recurrent or metastatic cancers including ongoing cohorts in locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC) intended to support one or more applications for marketing approval. In addition, it is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, which is an epidermal growth factor receptor (EGFR) inhibitor as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC).